Tocilizumab could reduce Mortality in severe COVID-19

被引：0
|
作者：
Ruchalla, Elke
机构：
来源：
PNEUMOLOGIE | 2021年 / 75卷 / 05期
关键词：
D O I：
10.1055/a-1441-1159
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Die Letalitat von COVID-19 liegt zwischen 35 und 62%, sodass die Suche nach wirksamen Therapien ungebrochen ist. Zusatzlich zu direkt antiviral wirkenden Medikamenten wie Remdesivir werden dabei auch Substanzen verwendet, die am Immunsystem der Patienten ansetzen. Sie sollen u.a. die oft fatale uberma ss ige Freisetzung proinflammatorischer Zytokine (Zytokinsturm") verhindern.
引用
收藏
页数：1
相关论文
共 50 条
  • [1] TOCILIZUMAB DID NOT REDUCE MORTALITY IN SEVERE COVID-19 PATIENTS BUT CAUSED THROMBOCYTOSIS
    Ozturk, Z.
    Turk, S. M.
    Karatas, D.
    Erkorkmaz, U.
    Suner, K. Ozmen
    Dheir, H.
    Guclu, E.
    Gonullu, E.
    Karabay, O.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1382 - 1382
  • [2] Impact of tocilizumab administration on mortality in severe COVID-19
    Tsai, Andrew
    Diawara, Oumou
    Nahass, Ronald G.
    Brunetti, Luigi
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [3] Impact of tocilizumab administration on mortality in severe COVID-19
    Andrew Tsai
    Oumou Diawara
    Ronald G. Nahass
    Luigi Brunetti
    [J]. Scientific Reports, 10
  • [4] Why tocilizumab could be an effective treatment for severe COVID-19?
    Binqing Fu
    Xiaoling Xu
    Haiming Wei
    [J]. Journal of Translational Medicine, 18
  • [5] Predictors of mortality in tocilizumab treated severe covid-19
    Pagkratis, K.
    Chrysikos, S.
    Antonakis, E.
    Pandi, A.
    Kosti, C.
    Markatis, E.
    Hillas, G.
    Digalaki, A.
    Koukidou, S.
    Chaini, E.
    Afthinos, A.
    Dimakou, K.
    Papanikolaou, I.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [6] Why tocilizumab could be an effective treatment for severe COVID-19?
    Fu, Binqing
    Xu, Xiaoling
    Wei, Haiming
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [7] Tocilizumab in severe COVID-19
    Liberato, Nicola Lucia
    De Monte, Andrea
    Caravella, Giuseppe
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (06) : 1457 - 1458
  • [8] Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
    Pagkratis, Konstantinos
    Chrysikos, Serafeim
    Antonakis, Emmanouil
    Pandi, Aggeliki
    Kosti, Chrysavgi Nikolaou
    Markatis, Eleftherios
    Hillas, Georgios
    Digalaki, Antonia
    Koukidou, Sofia
    Chaini, Eleftheria
    Afthinos, Andreas
    Dimakou, Katerina
    Papanikolaou, Ilias C.
    [J]. VACCINES, 2022, 10 (06)
  • [9] Tocilizumab for severe COVID-19 pneumonia
    Mourad, Jean-Jacques
    Azria, Philippe
    [J]. LANCET RHEUMATOLOGY, 2020, 2 (11): : E659 - E659
  • [10] Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
    Talaschian, Mona
    Akhtari, Maryam
    Mahmoudi, Mahdi
    Mostafaei, Shayan
    Jafary, Mohamadreza
    Jalali, Seyyed Mostafa
    Sadeghi, Kourosh
    Moghadam, Keivan Gohari
    Tadi, Hengameh Ansari
    Jamshidi, Ahmadreza
    [J]. IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2024, 23 (01) : 82 - 96
12345